Is Phibro Animal Health Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential.
In comparison to its peers, Phibro Animal Health Corp. has a more favorable valuation with a PEG ratio of 0.12, while Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. are both considered risky with negative P/E ratios. The stock has outperformed the S&P 500 with a year-to-date return of 89.14% compared to the index's 13.30%, reinforcing the notion that it is fairly valued in the current market context.